Related Experiment Video
Updated: Jan 9, 2026
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Effect of Dipyridamole on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17
Binyao Chen1, Zhaohao Huang2,3, Junjie Chen1
1Zhongshan Ophthalmic Center, Sun Yat-Sen University, WHO Collaborating Centre for Eye Care and Vision, State Key Laboratory of Ophthalmology, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Dipyridamole (DIP) shows promise for treating noninfectious uveitis by reducing inflammation and modulating immune cells. This phosphodiesterase (PDE) inhibitor may offer a new targeted therapy for this sight-threatening autoimmune eye disease.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Noninfectious uveitis is a severe autoimmune eye condition with limited targeted treatments.
- Dipyridamole (DIP), a phosphodiesterase (PDE) inhibitor, has known anti-inflammatory effects but its role in uveitis is unstudied.
Purpose of the Study:
- To investigate the potential of dipyridamole (DIP) as a targeted therapy for noninfectious uveitis.
- To explore the association between PDE gene expression and uveitis development.
- To assess the therapeutic efficacy of DIP in experimental autoimmune uveitis (EAU) models.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) was used on data from EAU mice and human uveitis patients.
- EAU mice were treated with DIP at preventative, early, or late stages.
- Cervical draining lymph nodes (CDLNs) and spleens were analyzed using scRNA-seq and other experiments.
Main Results:
- PDE gene expression correlated with uveitis severity in humans and mice.
- Preventative DIP treatment significantly reduced inflammation and modulated T cell balance (Teff/Treg).
- DIP suppressed T cell proliferation and pathogenicity, downregulating the cAMP-STAT3-PIM1 axis in Th17 cells.
Conclusions:
- Dipyridamole (DIP) effectively ameliorates intraocular inflammation in experimental autoimmune uveitis (EAU).
- DIP modulates the Th17/Treg balance and reduces Th17 cell pathogenicity, likely through the cAMP-STAT3-PIM1 pathway.
- DIP presents a promising therapeutic candidate for autoimmune uveitis.
